Super enhancers at the miR-146a and miR-155 genes contribute to self-regulation of inflammation

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1859, Issue 4, 2016, Pages 564-571

  Duan, Qiong ^a   Mao, Xiaoxiao ^a,b   Xiao, Yi ^a   Liu, Zhenzhen ^a   Wang, Yangui ^a,c   Zhou, Haoyang ^a   Zhou, Zhengxiang ^a   Cai, Jinxing ^d   Xia, Ke ^a   Zhu, Qubo ^e   Qi, Jun ^b   Huang, He ^d   Plutzky, Jorge ^b   Yang, Tianlun ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Department of Obstetrics and Gynecology   (China)

^d Central South University   (China)

^e CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

BET bromodomain; Inflammation; MicroRNA; NF B; Super enhancer

Indexed keywords

MICRORNA 146A; MICRORNA 155; RNA; BRD4 PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MICRORNA; MIRN146 MICRORNA, HUMAN; MIRN155 MICRORNA, HUMAN; NUCLEAR PROTEIN; RNA POLYMERASE II; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ARTICLE; AUTOREGULATION; ENHANCER REGION; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY;

ANIMALS; ENHANCER ELEMENTS, GENETIC; GENE EXPRESSION REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; MICE; MICRORNAS; NF-KAPPA B; NUCLEAR PROTEINS; RNA POLYMERASE II; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 84959431868     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2016.02.004     Document Type: Article

References (33)

1. Kotas M.E., Medzhitov R. Homeostasis, inflammation, and disease susceptibility. Cell 2015, 160:816-827.
2. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
3. Medzhitov R., Schneider D.S., Soares M.P. Disease tolerance as a defense strategy. Science 2012, 335:936-941.
4. Cinel I., Opal S.M. Molecular biology of inflammation and sepsis: a primer. Crit. Care Med. 2009, 37:291-304.
5. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
6. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 352:1685-1695.
7. Foster S.L., Hargreaves D.C., Medzhitov R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007, 447:972-978.
8. Cheng H.S., Sivachandran N., Lau A., Boudreau E., Zhao J.L., Baltimore D., Delgado-Olguin P., Cybulsky M.I., Fish J.E. MicroRNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways. EMBO Mol. Med. 2013, 5:949-966.
9. Brown J.D., Lin C.Y., Duan Q., Griffin G., Federation A.J., Paranal R.M., Bair S., Newton G., Lichtman A.H., Kung A.L., Yang T., Wang H., Luscinskas F.W., Croce K.J., Bradner J.E., Plutzky J. NF-kappaB directs dynamic super enhancer formation in inflammation and atherogenesis. Mol. Cell 2014, 56:219-231.
10. Nicodeme E., Jeffrey K.L., Schaefer U., Beinke S., Dewell S., Chung C.W., Chandwani R., Marazzi I., Wilson P., Coste H., White J., Kirilovsky J., Rice C.M., Lora J.M., Prinjha R.K., Lee K., Tarakhovsky A. Suppression of inflammation by a synthetic histone mimic. Nature 2010, 468:1119-1123.
11. Loven J., Hoke H.A., Lin C.Y., Lau A., Orlando D.A., Vakoc C.R., Bradner J.E., Lee T.I., Young R.A. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013, 153:320-334.
12. Hnisz D., Abraham B.J., Lee T.I., Lau A., Saint-Andre V., Sigova A.A., Hoke H.A., Young R.A. Super-enhancers in the control of cell identity and disease. Cell 2013, 155:934-947.
13. Lee Y., Kim M., Han J., Yeom K.H., Lee S., Baek S.H., Kim V.N. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004, 23:4051-4060.
14. Ozsolak F., Poling L.L., Wang Z., Liu H., Liu X.S., Roeder R.G., Zhang X., Song J.S., Fisher D.E. Chromatin structure analyses identify miRNA promoters. Genes Dev. 2008, 22:3172-3183.
15. Taganov K.D., Boldin M.P., Chang K.J., Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:12481-12486.
16. Tili E., Michaille J.J., Cimino A., Costinean S., Dumitru C.D., Adair B., Fabbri M., Alder H., Liu C.G., Calin G.A., Croce C.M. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J. Immunol. 2007, 179:5082-5089.
17. Boldin M.P., Baltimore D. MicroRNAs, new effectors and regulators of NF-kappaB. Immunol. Rev. 2012, 246:205-220.
18. Siomi H., Siomi M.C. Posttranscriptional regulation of microRNA biogenesis in animals. Mol. Cell 2010, 38:323-332.
19. Ha M., Kim V.N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 2014, 15:509-524.
20. Smalheiser N.R. Regulation of mammalian microRNA processing and function by cellular signaling and subcellular localization. Biochim. Biophys. Acta 2008, 1779:678-681.
21. Whyte W.A., Orlando D.A., Hnisz D., Abraham B.J., Lin C.Y., Kagey M.H., Rahl P.B., Lee T.I., Young R.A. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 2013, 153:307-319.
22. Creyghton M.P., Cheng A.W., Welstead G.G., Kooistra T., Carey B.W., Steine E.J., Hanna J., Lodato M.A., Frampton G.M., Sharp P.A., Boyer L.A., Young R.A., Jaenisch R. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:21931-21936.
23. Pott S., Lieb J.D. What are super-enhancers?. Nat. Genet. 2015, 47:8-12.
24. Zhu N., Zhang D., Chen S., Liu X., Lin L., Huang X., Guo Z., Liu J., Wang Y., Yuan W., Qin Y. Endothelial enriched microRNAs regulate angiotensin II-induced endothelial inflammation and migration. Atherosclerosis 2011, 215:286-293.
25. Yang H., Schramek D., Adam R.C., Keyes B.E., Wang P., Zheng D., Fuchs E. ETS family transcriptional regulators drive chromatin dynamics and malignancy in squamous cell carcinomas. ELIFE 2015, 4.
26. Yang Z., Yik J.H., Chen R., He N., Jang M.K., Ozato K., Zhou Q. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol. Cell 2005, 19:535-545.
27. Jang M.K., Mochizuki K., Zhou M., Jeong H.S., Brady J.N., Ozato K. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol. Cell 2005, 19:523-534.
28. Hargreaves D.C., Horng T., Medzhitov R. Control of inducible genes expression by signal-dependent transcriptional elongation. Cell 2009, 138:129-145.
29. Cordes K.R., Sheehy N.T., White M.P., Berry E.C., Morton S.U., Muth A.N., Lee T.H., Miano J.M., Ivey K.N., Srivastava D. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009, 460:705-710.
30. Rangrez A.Y., Massy Z.A., Metzinger-Le M.V., Metzinger L. miR-143 and miR-145: molecular keys to switch the phenotype of vascular smooth muscle cells. Circ. Cardiovasc. Genet. 2011, 4:197-205.
31. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., Morse E.M., Keates T., Hickman T.T., Felletar I., Philpott M., Munro S., McKeown M.R., Wang Y., Christie A.L., West N., Cameron M.J., Schwartz B., Heightman T.D., La Thangue N., French C.A., Wiest O., Kung A.L., Knapp S., Bradner J.E. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
32. Bailey D., Jahagirdar R., Gordon A., Hafiane A., Campbell S., Chatur S., Wagner G.S., Hansen H.C., Chiacchia F.S., Johansson J., Krimbou L., Wong N.C., Genest J. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J. Am. Coll. Cardiol. 2010, 55:2580-2589.
33. Delmore J.E., Issa G.C., Lemieux M.E., Rahl P.B., Shi J., Jacobs H.M., Kastritis E., Gilpatrick T., Paranal R.M., Qi J., Chesi M., Schinzel A.C., McKeown M.R., Heffernan T.P., Vakoc C.R., Bergsagel P.L., Ghobrial I.M., Richardson P.G., Young R.A., Hahn W.C., Anderson K.C., Kung A.L., Bradner J.E., Mitsiades C.S. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.